Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Clinical management of epidermal growth factor receptor mutation-positive non-small cell lung cancer patients after progression on previous epidermal growth factor receptor tyrosine kinase inhibitors: the necessity of repeated molecular analysis.

González-Larriba JL, Lázaro-Quintela M, Cobo M, Dómine M, Majem M, García-Campelo R.

Transl Lung Cancer Res. 2017 Dec;6(Suppl 1):S21-S34. doi: 10.21037/tlcr.2017.10.03. Review.

2.

Epidermal growth factor receptor T790M mutation as a prognostic factor in EGFR-mutant non-small cell lung cancer patients that acquired resistance to EGFR tyrosine kinase inhibitors.

Ma G, Zhang J, Jiang H, Zhang N, Yin L, Li W, Zhou Q.

Oncotarget. 2017 Jul 29;8(59):99429-99437. doi: 10.18632/oncotarget.19681. eCollection 2017 Nov 21.

3.

PKPD modeling of acquired resistance to anti-cancer drug treatment.

Eigenmann MJ, Frances N, Lavé T, Walz AC.

J Pharmacokinet Pharmacodyn. 2017 Dec;44(6):617-630. doi: 10.1007/s10928-017-9553-x. Epub 2017 Oct 31.

4.

Continuing EGFR-TKI beyond radiological progression in patients with advanced or recurrent, EGFR mutation-positive non-small-cell lung cancer: an observational study.

Goto Y, Tanai C, Yoh K, Hosomi Y, Sakai H, Kato T, Kaburagi T, Nishio M, Kim YH, Inoue A, Hasegawa Y, Isobe H, Tomizawa Y, Mori Y, Minato K, Yamada K, Ohashi Y, Kunitoh H.

ESMO Open. 2017 Sep 14;2(4):e000214. doi: 10.1136/esmoopen-2017-000214. eCollection 2017.

5.

Dynamic circulating tumor DNA quantificaton for the individualization of non-small-cell lung cancer patients treatment.

Provencio M, Torrente M, Calvo V, Gutiérrez L, Pérez-Callejo D, Pérez-Barrios C, Barquín M, Royuela A, Rodriguez-Alfonso B, Sotelo M, Cruz-Bermúdez JL, Mendez M, Cruz-Bermúdez A, Romero A.

Oncotarget. 2017 Aug 7;8(36):60291-60298. doi: 10.18632/oncotarget.20016. eCollection 2017 Sep 1.

6.

Continuous EGFR tyrosine kinase inhibitor treatment with or without chemotherapy beyond gradual progression in non-small cell lung cancer patients.

Peng L, Wang Y, Tang Y, Zeng L, Liu J, Zeng Z, Liu J, Shi P, Ye X, Zhao Q.

Onco Targets Ther. 2017 Aug 28;10:4261-4267. doi: 10.2147/OTT.S143569. eCollection 2017.

7.

TKI-addicted ROS1-rearranged cells are destined to survival or death by the intensity of ROS1 kinase activity.

Ogura H, Nagatake-Kobayashi Y, Adachi J, Tomonaga T, Fujita N, Katayama R.

Sci Rep. 2017 Jul 17;7(1):5519. doi: 10.1038/s41598-017-05736-9.

8.

Clinical Implications of the T790M Mutation in Disease Characteristics and Treatment Response in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC).

Gaut D, Sim MS, Yue Y, Wolf BR, Abarca PA, Carroll JM, Goldman JW, Garon EB.

Clin Lung Cancer. 2018 Jan;19(1):e19-e28. doi: 10.1016/j.cllc.2017.06.004. Epub 2017 Jun 20.

PMID:
28712979
9.

Immune-Related Tumor Response Dynamics in Melanoma Patients Treated with Pembrolizumab: Identifying Markers for Clinical Outcome and Treatment Decisions.

Nishino M, Giobbie-Hurder A, Manos MP, Bailey N, Buchbinder EI, Ott PA, Ramaiya NH, Hodi FS.

Clin Cancer Res. 2017 Aug 15;23(16):4671-4679. doi: 10.1158/1078-0432.CCR-17-0114. Epub 2017 Jun 7.

PMID:
28592629
10.

Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291).

Saad N, Poudel A, Basnet A, Gajra A.

Onco Targets Ther. 2017 Mar 22;10:1757-1766. doi: 10.2147/OTT.S100650. eCollection 2017. Review.

11.

Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer.

Uchibori K, Inase N, Araki M, Kamada M, Sato S, Okuno Y, Fujita N, Katayama R.

Nat Commun. 2017 Mar 13;8:14768. doi: 10.1038/ncomms14768.

12.

Development of personalized treatments in lung cancer: focusing on the EGFR mutations and beyond.

Suda K, Mitsudomi T.

Lung Cancer (Auckl). 2013 Aug 14;4:43-53. doi: 10.2147/LCTT.S49603. eCollection 2013. Review.

13.

Evolving Cancer Classification in the Era of Personalized Medicine: A Primer for Radiologists.

O'Neill AC, Jagannathan JP, Ramaiya NH.

Korean J Radiol. 2017 Jan-Feb;18(1):6-17. doi: 10.3348/kjr.2017.18.1.6. Epub 2017 Jan 5. Review.

14.
15.

Erlotinib-Conjugated Iron Oxide Nanoparticles as a Smart Cancer-Targeted Theranostic Probe for MRI.

Ali AA, Hsu FT, Hsieh CL, Shiau CY, Chiang CH, Wei ZH, Chen CY, Huang HS.

Sci Rep. 2016 Nov 11;6:36650. doi: 10.1038/srep36650.

16.
17.

Stereotactic body radiotherapy: current strategies and future development.

Tsang MW.

J Thorac Dis. 2016 Jul;8(Suppl 6):S517-27. doi: 10.21037/jtd.2016.03.14. Review.

18.

Leveraging Hypoxia-Activated Prodrugs to Prevent Drug Resistance in Solid Tumors.

Lindsay D, Garvey CM, Mumenthaler SM, Foo J.

PLoS Comput Biol. 2016 Aug 25;12(8):e1005077. doi: 10.1371/journal.pcbi.1005077. eCollection 2016 Aug.

19.

Targeted therapies and immunotherapy in non-small-cell lung cancer.

Cortinovis D, Abbate M, Bidoli P, Capici S, Canova S.

Ecancermedicalscience. 2016 Jun 23;10:648. doi: 10.3332/ecancer.2016.648. eCollection 2016. Review.

20.

Supplemental Content

Support Center